-
THE TOTAL COST OF CARE AND BUDGET IMPACT OF INTRODUCING MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN FOR SECOND-LINE OR LATER (2L+) TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL) TO A UNITED STATES (US) HEALTH PLAN
Mar 18, 2026, 21:38 PM -
COMPARISONS OF MEDICAL AND PRESCRIPTION DRUG EXPENDITURES BETWEEN AMERICANS WHO USED INSULIN GLARGINE LANTUS AND ITS INTERCHANGEABLE BIOSIMILAR SEMGLEE
Mar 18, 2026, 21:38 PM -
A COMPARATIVE ASSESSMENT OF TRAVEL BURDEN AND PRODUCTIVITY LOSS FOR CAR T-CELL THERAPY AND BISPECIFIC ANTIBODY TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY LBCL USING US CLAIMS DATA
Mar 18, 2026, 21:38 PM -
UNDERSTANDING PERSPECTIVES, BARRIERS AND ENABLERS FOR CLINICAL TRIAL PARTICIPATION IN REPRESENTATIVE PATIENT POPULATIONS
Mar 18, 2026, 21:38 PM -
OUT-OF-POCKET COST BURDEN AMONG PATIENTS DIAGNOSED WITH BREAST CANCER AND MENTAL HEALTH COMORBIDITIES: A CROSS-SECTIONAL STUDY USING MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA
Mar 18, 2026, 21:38 PM -
PHYSICAL ACTIVITY AND OUT OF POCKET HEALTH CARE EXPENDITURES AMONG BREAST CANCER SURVIVORS IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
MULTIMORBIDITY PATTERNS AMONG FUNCTIONALLY DEPENDENT ELDERLY ADULTS IN THE UNITED STATES: A LATENT CLASS ANALYSIS
Mar 18, 2026, 21:38 PM -
MENSTRUAL IRREGULARITY AND M-FRG SCORES: SHARED PREDICTORS OF DIAGNOSED AND HIGH-RISK PCOS IN UNIVERSITY STUDENTS
Mar 18, 2026, 21:38 PM -
PREOPERATIVE USE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS)AND SHORT-TERM POSTOPERATIVE OUTCOMES AFTER BARIATRIC SURGERY: A RETROSPECTIVE COHORT STUDY
Mar 18, 2026, 21:38 PM -
CAN PUBMED ALONE CAPTURE THE EVIDENCE BASE FOR TARGETED LITERATURE REVIEWS? A CASE STUDY
Mar 18, 2026, 21:38 PM -
INSIGHTS FOR AFFORDABILITY EFFORTS: ANALYZING DRUG AND NON-DRUG SPEND VIA STATE APCDS
Mar 18, 2026, 21:38 PM -
THE ECONOMIC BENEFIT OF A PRE-FILLED SYRINGE AS A ROUTE OF ADMINISTRATION: A TARGETED LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
EVOLVING COST-EFFECTIVENESS THRESHOLDS AT NICE: CHANGES IN THE BASE THRESHOLD AND USE OF HIGHER THRESHOLDS IN SPECIAL CASES
Mar 18, 2026, 21:38 PM -
ACCOUNTING FOR DIFFERENCES IN MAINTENANCE STUDY DESIGNS: METHODOLOGICAL CONSIDERATIONS FOR NMA
Mar 18, 2026, 21:38 PM -
COVERAGE COMPLETENESS AND TREATMENT COST ESTIMATION FOR ADMINISTERED DRUGS IN US COMMERCIAL PAYER PRICE TRANSPARENCY DATA
Mar 18, 2026, 21:38 PM -
GLP-1 THERAPY IMPROVES GLYCEMIC CONTROL WITH NO DIFFERENCE IN MEDICAL SPENDING: A REAL-WORLD EFFECTIVENESS STUDY
Mar 18, 2026, 21:38 PM -
UNDERSTANDING THE HEALTH-RELATED QUALITY OF LIFE BURDEN IN TRIGEMINAL NEURALGIA: A SYSTEMATIC LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
PATIENT-CENTERED ENDPOINT STRATEGY FOR BIOLOGIC TRIALS IN SEVERE ASTHMA: INTEGRATING REGULATORY, PAYER, AND PATIENT PRIORITIZED ENDPOINTS
Mar 18, 2026, 21:38 PM -
ESTIMATING THE MEDICAL UNMET NEED AND BURDEN OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
Mar 18, 2026, 21:38 PM -
NATIONAL TRENDS IN OPIOID, BENZODIAZEPINE AND ANTICHOLINERGIC ORDERS IN LONG-TERM CARE
Mar 18, 2026, 21:38 PM
